IPX066: a novel carbidopa-levodopa extended-release formulation. - Wikidata - awgldk - TriplyDB

IPX066: a novel carbidopa-levodopa extended-release formulation.

IPX066: a novel carbidopa-levodopa extended-release formulation.

http://www.wikidata.org/entity/Q37979870

about

Therapy for Parkinson's disease: what is in the pipeline?Long-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery?IPX066: a new intermediate-and extended-release carbidopa-levodopa formulation.Management of motor and non-motor symptoms in Parkinson's disease.Continuous dopaminergic delivery to minimize motor complications in Parkinson's disease.Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs.Impact of Pharmacotherapy on Quality of Life in Patients with Parkinson's Disease.Carbidopa/Levodopa ER Capsules (Rytary(®), Numient™): A Review in Parkinson's Disease.Is there room for new non-dopaminergic treatments in Parkinson's disease?Health-related quality of life in Parkinson's: impact of 'off' time and stated treatment preferences.Extended-release oral capsule of carbidopa-levodopa in Parkinson disease.Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats.

P2860

Q26991826-AD364BCD-9DDD-4C38-B57C-59AAD7B2A083 Q36013084-BDBB072C-3A5C-4523-AD2C-25B0E4B67BDA Q37115650-2064417D-4A9E-44BF-B71D-A771E20A83FC Q37544096-989A75B2-270B-4238-A832-BA88A607332C Q38091653-5E4EAC9A-E82F-4522-A6AF-FAF83EB4C1D2 Q38112219-0731FEA2-E7F0-42A1-B9CA-3B5ED74F7AAD Q38179453-3233CE5F-A493-429F-8045-F916F7F1EC9F Q38476557-E7ED2943-AAC3-4E40-B89B-C1A9B15B8DC1 Q38675921-9DFC295C-5068-4F3B-9A4F-FE0F196A27B4 Q39505368-E2668E1F-EE68-48E4-9F5C-BEE338039701 Q41081334-4D8443A1-C290-462B-A689-2387B04B2458 Q49335971-9FCD14D2-F926-448B-B219-9B04A3FB7F14 Q54328579-13911424-4B73-4BB2-B9B5-092DDC1FA5D5

P2860

IPX066: a novel carbidopa-levodopa extended-release formulation.

http://www.wikidata.org/entity/Q37979870

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

IPX066: a novel carbidopa-levodopa extended-release formulation.

@en

IPX066: a novel carbidopa-levodopa extended-release formulation.

@nl

type

label

IPX066: a novel carbidopa-levodopa extended-release formulation.

@en

IPX066: a novel carbidopa-levodopa extended-release formulation.

@nl

prefLabel

IPX066: a novel carbidopa-levodopa extended-release formulation.

@en

IPX066: a novel carbidopa-levodopa extended-release formulation.

@nl

P1433

Q37979870-2BD70E34-8BD0-4A83-B552-E7D8BA88F9CA

P1476

Q37979870-4993DF42-2B7D-4626-9540-CBEB021E27BE

P2093

Q37979870-A2E5E137-71DC-496C-AB53-02EC74FF2887

P2860

Q37979870-0A757940-BA10-46DC-9A61-F40010501FEE

Q37979870-228086B5-E83F-45F7-9AE7-3C4CF4A3C4C7

Q37979870-37E1497C-442C-4C42-8641-92EC5EF7AFC2

Q37979870-41E06BAA-EE59-4A9A-A582-315D8686745D

Q37979870-4C2FDC45-1204-430C-BCD7-0A687DE84FCE

Q37979870-54CFDE62-E583-4677-88B7-31B9A1FE0707

Q37979870-5F30DE6C-7EA2-41D7-A016-1C1EDB139CEE

Q37979870-81339C2F-B99B-48F9-A0D5-94424BD62EF4

Q37979870-85BBC5C4-CBE3-43A9-9321-26F669158675

Q37979870-8928EC3E-7A69-49AA-9BB0-A1304C869C0C

P304

Q37979870-AD93B614-E48A-443A-AB9E-F18C67090E3B

P31

Q37979870-16F9E344-843F-442A-81A0-95DEA3EA3310

P356

Q37979870-20B1B7AA-E94C-4F75-9004-90A0CB02C119

P433

Q37979870-D70F6FB0-F7C8-4362-B1A3-D3CA11B47262

P478

Q37979870-A3268342-5415-4539-B663-75D383B4014F

P577

Q37979870-40839D94-5613-4DBD-8633-ED2CE5C4D463

P698

Q37979870-08493C30-B4F1-4FFF-983B-B4033E5DFD21

P921

Q37979870-ACED2578-C467-419F-A990-A850A3971C0E

P356

P1433

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

P1476

IPX066: a novel carbidopa-levodopa extended-release formulation.

@en

P2093

Robert A Hauser

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease

A double-blind, delayed-start trial of rasagiline in Parkinson's disease.

Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications.

Duodenal levodopa infusion for the treatment of Parkinson's disease.

Levodopa: past, present, and future.

Future treatments for Parkinson's disease: surfing the PD pipeline.

Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease.

Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.

Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.

Levodopa/carbidopa/entacapone (Stalevo).

P304

133-140

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERN.11.195

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22288668

http://www.w3.org/2001/XMLSchema#string

P921